





Tigecycline use in critically ill patients:
a multicentre prospective observational study
in the intensive care setting
Received: 28 January 2014
Accepted: 25 April 2014
Published online: 29 May 2014
 The Author(s) 2014. This article is
published with open access at
Springerlink.com
Take-home message: The efficacy and
safety of tigecycline in the treatment of
severe infections is consistent with other
antibiotics, regardless of disease severity.
No particular safety concerns were raised.
A related editorial can be found at doi:
10.1007/s00134-014-3343-3.
Electronic supplementary material
The online version of this article
(doi:10.1007/s00134-014-3323-7) contains
supplementary material, which is available
to authorized users.
P. Montravers ())
Department of Anesthesiology and Surgical
Intensive Care, Bichat-Claude Bernard
University Hospital Center, Paris Diderot
University, Sorbonne Paris-Cite´ and AP-
HP, 46 Rue Henri-Huchard, 75018 Paris,
France
e-mail: philippe.montravers@bch.aphp.fr
Tel.: ?33 140 25 83 55
H. Dupont
Department of Anesthesia and Critical Care
Medicine, Amiens University Hospital




Department of Intensive Care, Andre´
Mignot Hospital, Versailles, France
e-mail: jpbedos@ch-versailles.fr
P. Bret
Pfizer France, Paris, France
e-mail: Philippe.Bret@pfizer.com
Abstract Purpose: This prospec-
tive observational study aimed at
describing prescription patterns of
tigecycline and patient outcomes in
26 French intensive care units (ICU).
Methods: Data of consecutive cases
of adult patients treated with tigecy-
cline were collected from the
initiation until 7 days after the end of
treatment. Response to treatment was
classified as success, failure or unde-
termined and analyses were presented
according to severity (SOFA
score \7 or C7). Survival was
recorded at 28 days. Results: A
total of 156 patients were included
(64 % male, age 60 ± 15 years). At
inclusion, 53 % had a SOFA
score C7; 93 % had received prior
anti-infective agents. Tigecycline was
given as first-line treatment in 47 %
of patients, mostly in combination
(67 %), for intra-abdominal (IAI
56 %), skin and soft tissue (SSTI
19 %) or other infections. A total of
76 % of the treated infections were
hospital-acquired. Bacteraemia was
reported in 12 % of patients. Median
treatment duration was 9 days. Tige-
cycline was prematurely stopped in
42 % patients. The global success
rate was 60 % at the end of treatment,
and significantly higher with treat-
ment duration more than 9 days (76
vs. 47 %, P \ 0.001). Success rate
was 65 % for patients alive at the end
of treatment. Success rates tended to
decrease with illness severity, immu-
nosuppression, bacteraemia and
obesity. Survival rate at day 28 was
85 % in the whole cohort and signif-
icantly higher in the less severely ill
patients (P \ 0.001). Conclu-
sions: Tigecycline success rates
appear comparable to those reported
in clinical studies in ICU with severe
infections. Tigecycline could be an
alternative in ICU patients.
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Introduction
Tigecycline is one of the scarce available compounds,
with a broad-spectrum activity, effective against
multidrug-resistant strains including Gram-positive,
Gram-negative aerobic, anaerobic bacteria and atypical
microorganisms. In randomised controlled trials (RCT),
tigecycline was effective in the treatment of complicated
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skin and soft tissue infections (cSSTIs) [1–3], compli-
cated intra-abdominal infections (cIAIs) [4–7] and
community-acquired pneumonia (CAP) [8–10]. Addi-
tional studies showed that tigecycline was effective in
serious infections caused by known resistant pathogens
[11, 12].
However, the use of tigecycline in patients with severe
underlying diseases is limited, and little is known about
its efficacy [13–15]. To date, RCTs included few inten-
sive care unit (ICU) patients. Few data are available for
ICU patients with bacteraemia [16].
For these reasons, we carried out a prospective,
observational study in the intensive care setting to
describe tigecycline prescription patterns and outcomes
in critically ill patients from French ICUs. Some of our
results were recently published in a series of articles
reporting the ‘‘real-life’’ practice gathering five Euro-
pean databases (German, Italian, two Spanish studies
and the current cohort). These analyses focused on
labelled indications [17–19], global microbiology
results [20] and safety issues [21], but did not address
several key points, such as off-label indications, bac-
teraemia, emergence of resistance, superinfections and
long-term outcomes; this led us to consider this in-depth
analysis.
Materials and methods
Study design and patients
This prospective, multicentre, national observational
study included consecutive cases of adult ICU patients
treated with tigecycline. The only inclusion criterion was
the receipt of tigecycline therapy in any, approved or non-
approved, indication as mono- or combination, empiric,
documented or rescue therapy for a specific localised
source of infection or a specific flora. There was no rec-
ommendation on dosage or needed indication for the
study protocol.
In accordance with French law, approval of an ethics
committee was not required. The protocol was approved
by the institutional review board (CEERB, CHU Bichat,
Paris). All patients were informed of the data collection
and agreed to participate in the study. A scientific com-
mittee (the authors) independently designed the study and
reviewed all the collected data.
Clinical and microbiological data
Data were collected at ICU admission, at the start and end
of tigecycline treatment, and 7 days after the end of
treatment (or at hospital discharge if earlier). Clinical
data included demographics, underlying diseases [22]
(including diabetes mellitus, chronic renal failure, and
chronic liver failure assessed using the Child–Pugh score
[23]), immunosuppression (defined as steroid therapy or
cancer therapy), severity of illness (assessed using the
simplified acute physiology score (SAPS) II at ICU
admission [24] and the sequential organ failure assess-
ment (SOFA) score at the start of tigecycline treatment
[25]), and previous tigecycline therapy.
The tigecycline-treated infection was clinically and
microbiologically characterised. cIAIs (localised, gener-
alised peritonitis, etc.) and cSSTI (dermis-hypodermis,
fascia, etc.) were detailed as assessed during the surgery.
The infection site and hospital- or community-acquired
settings were collected.
The results of direct examinations and cultures were
recorded. Identification and in vitro sensitivity testing of
the pathogens were performed in the microbiology labo-
ratory of each hospital using routine methods. Isolates
were classified as susceptible (S), intermediate (I) or
resistant (R) to tigecycline according to European Com-
mittee on Antimicrobial Susceptibility Testing
(EUCAST) methodology. Data concerning persistent and
emerging isolates, including Pseudomonas aeruginosa,
were collected.
Treatment data
The reasons for choosing tigecycline and any anti-infec-
tive agents received in the previous 28 days were
recorded. The tigecycline regimen (loading dose, main-
tenance dose and treatment duration) and the associated
anti-infective agents were recorded.
Outcomes
Response to treatment was determined as clinical success/
failure at the end of tigecycline treatment and 7 days later
(or at hospital discharge if earlier). Success was defined
by the lack of need to use a new antibiotic or a surgical
treatment not initially planned for the initial infection.
Criteria for failure were persistence of the initial infection
signs requiring a change of antibiotic therapy or a surgical
intervention, reappearance of the initial infection signs,
infection-related death occurred later than 48 h after the
start of tigecycline and/or premature treatment discon-
tinuation due to a tigecycline-related adverse event.
Response was classified as undetermined in case of
insufficient data (e.g. de-escalation before the fourth day
of treatment), death not directly related to the initial
infection or occurred within the first 48 h of treatment, or
addition of an antibacterial agent for another infection.
Survival was recorded 28 days after the end of tigecycline
treatment: data were retrieved from the French national
epidemiology center for medical causes of death (Ce´piDc,
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Centre d’e´pide´miologie sur les causes me´dicales de de´ce`s,
INSERM).
Statistics
Data were analysed using SAS 8.2 (SAS Institute Inc.,
Cary, NC, USA). To describe a characteristic or an event
with a 10 % frequency and an accuracy of ±5 % as
assessed by the 95 % confidence interval (95 % CI), 150
patients were to be enrolled.
For the purpose of this study, patients’ characteristics
were stratified for disease severity assessed by SOFA score
(\7 or C7). Outcomes were stratified for SOFA score, body
mass index (BMI B35 kg and [35 kg/m2), immunosup-
pression, and age groups (\70 and C70 years of age).
Variables were expressed as median values and ranges
for numerical variables, and as frequencies and percent-
ages for categorical variables. The 95 % CIs of the
response rates were calculated. Groups were compared
using Wilcoxon signed-rank test for numerical variables,
and the Chi square or the Fisher’s exact test for cate-
gorical variables. Comparisons for success rates were
carried out under the worse assumption, i.e. considering
undetermined responses as failures. Factors independently
associated with success to treatment at 7 days were
identified by multivariate stepwise logistic regression
among the factors that were statistically significant at the
10 % level in univariate regressions and taking into
account significant interactions. The predictive perfor-
mance of the final multivariate model was evaluated using
receiver operating characteristic (ROC) analysis [26].
Survival, defined as the time from the first tigecycline
intake to 28 days after last intake (or death), whichever
occurs first, was assessed using the Kaplan–Meier
method. A log-rank test was performed for subgroup
analyses. As day-28 follow-up was not available for 18
patients, their survival time was censored at the time of
the last visit in the study. A death recorded after day 28
was censored at the time of day 28. Statistical signifi-
cance was accepted at the 5 % level.
Results
Patients’ clinical characteristics
A total of 156 patients from 26 ICUs were enrolled
between September 2008 and April 2010, including 73
patients with a SOFA score \7 and 83 severe cases
(SOFA C7) (Table 1). Immunosuppression was mainly
due to cancer (n = 29) and steroid therapy (n = 16).
The majority of patients (145/156, 93 %) had received
one or more anti-infective agents in the last 30 days
before the start of tigecycline [including penicillins
(60 %), cephalosporins (42 %), aminoglycosides (39 %),
carbapenems (28 %), glycopeptides (26 %) or fluoro-
quinolones (26 %)].
Infections treated with tigecycline
Tigecycline was given for the treatment of cIAI in 88/156
(56 %) patients, cSSTI in 29 (19 %) and other infections
in 56 (36 %) (mainly lung infections, n = 38, 24 %)
(Table 1). Most of the treated infections were hospital-
acquired (131/173, 76 %). A positive blood culture was
observed in 17 (12 %) patients. Overall, 17/145 (12 %)
patients had secondary bacteraemia, including 9/63
(12 %) patients with a SOFA score C7 (P = 0.963).
Indications for tigecycline were similar in the less and the
most severely ill patients.
Microbiological data
Overall, 146 (94 %) patients had at least one microbio-
logical sample at the start of tigecycline [direct
examination in 87 (56 %) patients, species identified in
127 (81 %) patients] (Table 2). Infection was polymi-
crobial in 29 cases. There were no marked differences
between the less and the most severely ill patients (data
not shown).
Three microorganisms in three patients acquired
resistance to tigecycline during the course of treatment
(Escherichia coli, Enterobacter cloacae and Enterobacter
aerogenes). Sixty-four microorganisms in 41 patients
emerged during the course or at the end of treatment: 18
Gram-positive cocci (including 11 staphylococci), 39
Gram-negative bacilli (including 9 P. aeruginosa, 6
Enterobacter ssp., 3 Proteus ssp., and 1 Morganella
morganii), 4 anaerobic germs and 3 yeasts. A total of 28
microorganisms in 23 patients persisted with no change in
susceptibility (both emergence and persistence were
observed in 13 of these 23 patients) during the course of
tigecycline treatment: 11 Gram-positive cocci (5 entero-
cocci and 6 staphylococci) and 16 Gram-negative bacilli
(including 6 E. coli, 4 Klebsiella spp. and 3 other
enterobacteria).
Treatment with tigecycline
Characteristics of treatment are provided in Table 1. The
vast majority of patients were given the recommended
loading and maintenance doses with an overall median
treatment duration of 9 (1–78) days: 8 (1–78) days in the
less severely ill, 9 (2–43) days in the most severely ill
(P = 0.499) patients and 9 days (2–78) in patients alive
at the end of treatment. Tigecycline was combined with
other anti-infective agents in two-thirds of the patients
(101/156, 65 %) (Fig. 1), without statistically significant
990
Table 1 Treatment with tigecycline: patients’ characteristics at baseline, types of infections treated and characteristics of treatment
SOFA \7 SOFA C7 Total P value
n = 73 n = 83 n = 156
Patients’ clinical characteristics at the start of tigecycline treatment
Demographics
Age (years) 61 (19–84) 63 (27–86) 62 (19–86) 0.268
Age C70 years 26/52 (50) 26/52 (50) 52/156 (33) 0.362
Male gender 42/73 (58) 58/83 (70) 100/156 (64) 0.109
BMI (kg/m2) 26 (16–58) 27 (17–51) 26 (16–58) 0.577
BMI [35 kg/m2 7/64 (11) 10/78 (13) 17/142 (12) 0.731
Severity of disease
SAPS II on admission in ICU 35 (3–78) 48 (12–99) 42 (3–99) \0.001
SOFA 3 (0–6) 10 (7–24) 7 (0–24) \0.001
Hemodynamic failure 4/73 (6) 12/83 (15) 16/156 (10)
Respiratory failurea 9/73 (12) 41/83 (49) 50/156 (32)
Renal failureb 2/73 (3) 26/83 (31) 28/156 (18)
Underlying disease 0.868
Ultimately fatal 19/73 (26) 21/82 (26) 40/155 (26)
Rapidly fatal 7/73 (10) 6/82 (7) 13/155 (8)
Immunosuppression 23/73 (32) 29/83 (35) 52/156 (33) 0.650
Diabetes mellitus 12/73 (16) 18/83 (22) 30/156 (19) 0.771
Chronic renal failure 4/73 (5) 12/83(15) 16/156 (10) 0.110
Chronic liver failure 1/73 (1) 4/83 (5) 5/156 (3) 0.372
Prior anti-infective agents (last 30 days) 68/73 (93) 77/83 (93) 145/156 (93) 0.926
Types of infections treated with tigecycline
Intra-abdominal infection 37/73 (51) 51/83 (61) 88/156 (56) 0.176
Hospital-acquired 26/37 (70) 35/51 (69) 61/88 (69)
Localised peritonitis 7/26 (27) 3/42 (7) 10/68 (15)
Abscess without peritonitis 6/26 (23) 9/42 (21) 15/68 (22)
Localisation
Colon 15/37 (41) 25/51 (49) 40/88 (45)
Small intestine 10/37 (24) 9/51 (18) 18/88 (20)
Stomach/duodenum 6/37 (16) 5/51 (10) 11/88 (12)
Other site 10/37 (27) 18/51 (35) 28/88 (32)
Skin and soft tissues infection 14/73 (19) 15/83 (18) 29/156 (19) 0.859
Hospital-acquired 10/14 (71) 10/15 (67) 20/29 (69)
Dermohypodermitis 13/14 (93) 15/15 (100) 28/29 (97)
Localisation
Abdomen 3/8 (38) 7/9 (78) 10/17 (59)
Head and neck 4/8 (50) 1/9 (11) 5/17 (29)
Other infection 26/73 (36) 30/83 (36) 56/156 (36) 0.945
Hospital-acquired 23/26 (89) 27/30 (90) 50/56 (89)
Lung 17/26 (66) 21/30 (70) 38/56 (68)
Characteristics of treatment with tigecycline
Treatment line intended 0.045
Empiric 38/73 (52) 35/83 (42) 73/156 (47)
Documentedc 27/73 (37) 45/83 (54) 72/156 (46)
Reason for choosing tigecycline
Polymicrobial infection 37/73 (51) 49/83 (59) 86/156 (55) 0.295
Multiresistant bacteria suspected/identified 28/73 (38) 35/83 (42) 63/156 (40) 0.628
Renal failure 7/73 (10) 21/83 (25) 28/156 (18) 0.011
Multiple site infection 8/73 (11) 16/83 (19) 24/156 (15) 0.151
Failure of previous treatment 6/73 (8) 13/83 (16) 19/156 (12) 0.156
Allergy/intolerance to another antibacterial agent 9/73 (12) 6/83 (7) 15/156 (10) 0.281
Rescue treatment 8/73 (11) 5/83 (6) 13/156 (8) 0.266
Other 5/73 (7) 5/83 (6) 10/156 (6) 0.834
Loading dose of 100 mg 70/73 (96) 82/83 (99) 152/156 (97) 0.341
Maintenance dose of 50 mg bid 68/73 (93) 78/83 (94) 146/156 (94) 0.859
Data are median values (range) or n/N (%) of patients, with
N = number of available data
BMI body mass index, ICU intensive care unit, SAPS simplified
acute physiology score, SOFA sequential organ failure assessment
a SOFA subscore of 3 or 4 (on a 0–4 scale)
b SOFA subscore of 3 or 4 (on a 0–4 scale); chronic renal failures
are not included
c Including rescue treatments
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difference between groups (64 vs. 65 % for the \70 and
C70 years age groups, respectively, P = 0.906; and 63
vs. 66 % for the SOFA \7 and C7 groups, respectively,
P = 0.671). The aminoglycosides used were amikacin
(17 % of all patients) and gentamicin (8 %). The most
frequently used penicillin was piperacillin (combined
with tazobactam, 11 %).
Tigecycline treatment was prematurely stopped in 66
(42 %) patients, without statistically significant difference
according to the illness severity (P = 0.774). The reasons
were resistant strain included (n = 11), clinical failure
(n = 12), de-escalation (n = 20), death (n = 14), new
infection (n = 4), persistent fever of unknown origin
(n = 1), unjustified antibacterial agent change (n = 1)
and/or shock probably not of infectious origin (n = 1). In
the less severely ill patients, the most common reasons
were de-escalation (10/37, 33 %) and resistant strain
(n = 8), whereas in the most severely ill patients they
were death (12/36, 33 %) and de-escalation (n = 10).
Adverse events were reported in 16 and 29 % of the less
and most severely ill patients, respectively (23 % of total
patients). Three adverse events were considered as probably/
definitely related to tigecycline: drug resistance (n = 1),
drug inefficacy (death due to septic shock, n = 1) and acute
renal failure (patient cured with tigecycline, n = 1). Irre-
spective of causality, serious adverse events (fatal or not)
occurred in 10 and 23 % of the less and most severely ill
patients, respectively (17 % of total patients).
Response to treatment
The overall success rate was 60 % [93/156, 95 % CI
(51–67)] at the end of treatment, and 53 % [77/145, 95 %
CI (45–61)] 7 days after the end of treatment (Table 3).
The difference in success rates between the less and the
most severely ill patients was significant at both time
points (P = 0.005, P = 0.001, respectively). The success
rate at the end of treatment for patients alive after the last
tigecycline uptake was 65 % [92/141, 95 % CI (57–73)].
The causes of failure at the end of treatment are described
in Table 3. Table 4 provides the success rates obtained in
the patient subgroups of interest, 7 days after the end of
treatment.
The success rate at 7 days after treatment was statis-
tically significantly higher when tigecycline treatment
duration was longer. In the whole cohort, the success rate
was 70 % with a treatment duration [9 days vs. 40 %
with a treatment duration B9 days (P \ 0.001). Similarly,
it was 80 vs. 55 % (P = 0.097) respectively, in the less
severely ill patients and 61 vs. 27 %, respectively, in the
most severely ill patients (P = 0.008). Combination of
another antibiotic with tigecycline did not markedly
influence the success rate in the whole cohort, in the less
and in the most severely ill patients (54 vs. 51 %; 67 vs.
64 %; 42 vs. 39 %, respectively).
A reduced rate, although not statistically significant,
was observed with concomitant bacteraemia vs. without
Table 2 Number (%) of baseline isolates by sensitivity to tigecycline
Total isolates Susceptiblea Intermediate or resistanta
Total 250 (100) 108 (83.7) 21 (16.3)
Aerobes 221 (88.4) 104 (83.2) 21 (16.8)
Gram-positive cocci 103 (41.2) 50 (96.2) 2 (3.8)
Enterococci 51 (20.4) 29 (93.5) 2 (6.5)
Enterococcus faecalis 16 (6.4) 6 (85.7) 1 (14.3)
Enterococcus faecium 21 (8.4) 12 (92.3) 1 (7.7)
Staphylococci 36 (14.4) 16 (100)
Staphylococcus aureus 20 (8.0) 10 (100)
Streptococci 16 (6.4) 5 (100)
Gram-negative bacilli 118 (47.2) 54 (74.0) 19 (26.0)
Enterobacteriaceae 89 (35.6) 41 (74.5) 14 (25.5)
Escherichia coli 44 (17.6) 23 (95.8) 1 (4.2)
Klebsiella spp. 18 (7.2) 8 (61.5) 5 (38.5)
Enterobacter spp. 14 (5.6) 8 (72.7) 3 (27.3)
Serratia spp. 4 (1.6) 1 (33.3) 2 (66.7)
Citrobacter 2 (0.8) 1 (50.0) 1 (50.0)
Proteus spp. 6 (2.4) 1 (100)
Morganella spp. 1 (0.4) 1 (100)
Non-fermenting Gram-negative bacilli 15 (6.0) 5 (50.0) 5 (50.0)
Pseudomonas aeruginosa 6 (2.4) 1 (100)
Stenotrophomonas maltophilia 8 (3.2) 5 (62.5) 3 (37.5)
Acinetobacter baumannii 1 (0.4) 1 (100)
Other Gram-negative strains 14 (5.6) 8 (100)
Anaerobes 18 (7.2) 4 (100)
Bacteroides fragilis 6 (2.4) 1 (100)
Other anaerobes 12 (4.8) 3 (100)
Pathogens, no further specified 3 (1.2)
a Percentage of isolates for which the sensitivity to tigecycline was known
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bacteraemia, in the less (62 vs. 74 %) and in the most
severely ill patients (33 vs. 54 %).
Univariate regressions identified two factors associ-
ated with failure of treatment at 7 days: the SOFA score,
either expressed as increasing SD units [OR = 1.72,
95 % CI (1.20–2.50), P = 0.003] or a score C7
[OR = 2.70, 95 % CI (1.39–5.26), P = 0.004], and BMI,
either expressed as increasing SD units [OR = 9.09,
95 % CI (1.92–50), P = 0.005] or a BMI [35 kg/m2
[OR = 1.39, 95 % CI (0.96–2.00), P = 0.080]. The fac-
tors associated with failure and identified using the
multivariate analysis were an increasing SOFA score
[OR = 1.67, 95 % CI (1.12–2.44), P = 0.010] and a
BMI [35 kg/m2 [OR = 8.33, 95 % CI (1.82–33.33),
P = 0.007]. The sensitivity and specificity of this model
were 94 % [95 % CI (0.88–1.00)] and 37 % [95 % CI
(0.25–0.49)], respectively.
Survival
Global survival at 28 days was 85 % and no statistical dif-
ference was observed between age groups (87 vs. 80 % for
the \70 and C70 years age groups, respectively,
P = 0.408). Survival at day 28 was higher in patients with a





































Fig. 1 Anti-infective agents combined with tigecycline
Table 3 Response to treatment with tigecycline
SOFA \7 SOFA C7 Total P value
n = 73 n = 83 n = 156
At the end of treatment
Success 51/73 (70) 42/83 (51) 93/156 (60) 0.005
Failure 14/73 (19) 14/83 (17) 28/156 (18)
Persistence of the initial infection signs requiring
a change of antibiotic therapy or a surgical intervention
5 7 12
Infection-related death occurred later than 48 h
after the start of tigecycline
1 3 4
Clinical failure 8 4 12
Undetermined 8/73 (11) 27/83 (33) 35/156 (22)
Insufficient data 4 6 10
Death not directly related to the initial infection
or occurred within the first 48 h of tigecycline treatment
1 11 12
Addition of an antibacterial agent for the treatment
of an infection different from the initial one
3 10 13
7 days after the end of treatment
Success 46/70 (66) 31/75 (41) 77/145 (53) 0.001
Failure 16/70 (23) 16/75 (21) 32/145 (22)
Reappearance of the initial infection signs 16 16 32
Undetermined 8/70 (11) 28/75 (37) 36/145 (25)
Insufficient data 4 6 10
Death not directly related to the initial infection 1 11 12
Addition of an antibacterial agent for the treatment
of an infection different from the initial one
3 11 14
Data are n/N (%) of patients, with N = number of available data
SOFA sequential organ failure assessment
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P = 0.003) and statistically significantly higher in the less
than in the most severely ill patients (96 vs. 75 %,
P \ 0.001) (electronic supplementary material). Moreover,
patients receiving catecholamines treatment had a statisti-
cally significant lower survival rate than those not treated
with catecholamines (75 vs. 94 %, P = 0.001). Survival at
day 28 was 86, 93 and 80 % for the patients initially suf-
fering from IAI, SSTI and other infections, respectively.
Discussion
The efficacy of tigecycline versus other antimicrobial
agents for the treatment of cSSTI [1–3] and cIAI [4–7, 27]
has been evidenced in several RCTs, demonstrating that
tigecycline was as efficacious as the comparators in
treating infections, with a comparable safety profile.
Three recent meta-analyses evaluating the published data
from available RCTs also found no statistically significant
difference in treatment success between cIAI patients treated
with tigecycline and those treated with comparators [28–30].
However, in both cSSTI and cIAI trials, severe cases were
usually excluded from the protocol, leading to insignificant
information about these particular cases.
Recently, the US Food and Drug Administration
(FDA) and the European Medicines Agency (EMA)
issued a warning regarding the risk of increased mortality
in patients treated with tigecycline, observed in the clin-
ical trials [31, 32]. In all phase III and IV (cSSTI and
cIAI) studies, death occurred in 2.4 % (54/2,216) of
patients receiving tigecycline and in 1.7 % (37/2,206) of
patients receiving comparator drugs [33]. A number of
meta-analyses also reported higher all-cause mortality in
patients treated with tigecycline versus comparators in
RCTs [28–30, 34, 35]. Taking into account these findings,
the EMA Committee for Medicinal Products for Human
Use concluded that tigecycline benefits continue to out-
weigh its risks, but recommended modifications in
product information to ensure an appropriate use, by
making prescribers aware of the observed increased
mortality risk. In addition, they issued a recommendation
stating that tigecycline should be used only when other
antibiotics are known or suspected to be not suitable [33].
However, clinical trials concerning critically ill patients’
management are limited. A few large observational studies
have been set up to determine the outcomes of ICU tigecy-
cline-treated patients in clinical practice. The success rates
obtained in the current study are in line with those reported in
previous registries [13–15, 18] and in the European registry
[17–19]. Interestingly, the success rate is also comparable to
those reported in RCTs assessing the efficacy of other anti-
biotics in the ICU setting [36].
RCTs in contrast to registries generally do not reflect
the clinical practice and do not represent real-life patients
because of stringent selection criteria. This point is of
interest particularly in ICU patients, for whom a limited
number of trials are conducted only in selected indica-
tions. In addition, the evaluation endpoints used here were
selected to ensure that the physician’s concerns were
respected and obviously do not favour the product.
The tigecycline dosage used in this study stands in the
conventional range (100 mg daily) in 93–94 % of the cases.
Interestingly, a relatively satisfactory success rate was
reported in pulmonary infection patients. Similarly to other
antibiotic drugs [37], concerns have been raised about the
best dose for tigecycline, especially for treatment of pul-
monary infections. Recent publications suggest a potential
benefit of high dose tigecycline (200 mg daily) in severe/
difficult-to-treat infections [38]. Effectiveness and safety of
this policy without adding new risk factors for potentially
resistant bacteria remain to be confirmed [39].
The never-ending debate on bacteriostatic drugs use
for treatment of serious infections was re-triggered with
the launch of tigecycline [40]. In many ICUs across the
world, physicians dare to prescribe this bacteriostatic
agent without having the feeling of putting their patients
in jeopardy [13–15]. This point is particularly relevant in
patients receiving a monotherapy as a first-line treatment.
We, like others, report good results in monotherapy in
more than half of patients receiving tigecycline. In con-
trast to other countries, tigecycline seems to be used in
France mainly in combination with agents directed
Table 4 Success rate according to the major characteristics of
patients, infections and tigecycline treatment
Characteristics Success rate 7 days after
the end of tigecycline
P value
Patient
Age \70 years 50/94 (53) 0.937
Age C70 years 27/51 (53)
Not immunosuppressed 53/94 (56) 0.555
Immunosuppressed 24/51 (47)
BMI B35 kg/m2 65/116 (56) \0.001
BMI [35 kg/m2 2/16 (13)
Localisation of infection 0.402
cSSTI 17/27 (63)
cIAI 44/82 (54)
Pulmonary infection 17/37 (46)
No concomitant bacteraemia 66/118 (56) 0.492
Concomitant bacteraemia 8/17 (47)
Species at start of treatment 0.107
Gram-positive cocci 31/64 (48)
Enterobacteria 37/66 (56)
Anaerobes 10/11 (91)
Other bacteria 14/25 (56)
Tigecycline treatment
Duration B9 days 34/84 (40) \0.001
Duration [9 days 43/61 (70)
Monotherapy 23/45 (51) 0.747
Combination 54/100 (54)
Empiric therapy 38/70 (54) 0.783
Documented therapy 39/75 (52)
Data are n/N (%) of patients, with N = number of available data
cSSTI complicated skin and soft tissue infection, cIAI complicated
intra-abdominal infection
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particularly against Gram-negative microorganisms, and
the preferred indications are those of the marketing au-
thorisations. This finding was also reported in the
European registries [17–19]. For instance, in a severe ICU
population in Germany, tigecycline was also used mostly
in combination (76 %), but the therapy frequently tar-
geted Gram-positive cocci (including enterococci)
possibly because of the high frequency of vancomycin-
resistant strains. In Latin American countries, the tige-
cycline use in off-label indications appears to be
important [41].
Finally, there were no serious adverse events requiring
tigecycline discontinuation, and few tigecycline-related
adverse events were reported. It is important to note that
tigecycline administration in severe ICU patients, partic-
ularly in those with multiple organ failure, raised no
safety concerns.
Like all observational studies, the limitations of our
study included the lack of a control group and randomi-
sation. However, our results contribute to the knowledge
about tigecycline use in severely ill patients, a fragile
population lacking clinical data. It is interesting that no
increased mortality was observed in the cIAI and cSSTI
tigecycline-treated patients, as observed in the five dif-
ferent European registries.
From our experience, tigecycline could be proposed as
an empiric therapy in low severity cases, non-immuno-
suppressed or non-bacteraemic infections. In severe
infections, immunosuppressed, bacteraemic or obese
patients, its use should be cautiously considered, and
restricted to documented therapy based on susceptibility
testing in difficult-to-treat infections. Other options
should be considered for suspected P. aeruginosa infec-
tions [42, 43].
Conclusions
In this ICU population treated with tigecycline, the suc-
cess rates were comparable to those obtained in clinical
studies analysing severe infections. In contrast to its use
in other countries, tigecycline appears to be used mainly
in combination with agents directed particularly against
Gram-negative microorganisms.
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